Medline Inc. Class A Common Stock (MDLN)vsNephros Inc (NEPH)
MDLN
Medline Inc. Class A Common Stock
$32.53
+0.43%
HEALTHCARE · Cap: $43.58B
NEPH
Nephros Inc
$4.47
-1.11%
HEALTHCARE · Cap: $44.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 144379% more annual revenue ($29.94B vs $20.72M). NEPH leads profitability with a 8.4% profit margin vs 2.3%. NEPH trades at a lower P/E of 25.4x. NEPH earns a higher WallStSmart Score of 58/100 (C).
MDLN
Buy52
out of 100
Grade: C-
NEPH
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MDLN.
Margin of Safety
+12.6%
Fair Value
$4.62
Current Price
$4.47
$0.15 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 262.0% YoY
Reasonable price relative to book value
Revenue surging 36.2% year-over-year
Earnings expanding 450.0% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 20.2%
Areas to Watch
Distress zone — elevated risk
ROE of 6.0% — below average capital efficiency
2.3% margin — thin
Operating margin of 0.8%
Moderate valuation
Smaller company, higher risk/reward
ROE of 7.3% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MDLN
The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : NEPH
The strongest argument for NEPH centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 36.2% demonstrates continued momentum.
Bear Case : MDLN
The primary concerns for MDLN are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 42.6x leaves little room for execution misses. Thin 2.3% margins leave little buffer for downturns.
Bear Case : NEPH
The primary concerns for NEPH are P/E Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
MDLN profiles as a value stock while NEPH is a hypergrowth play — different risk/reward profiles.
NEPH is growing revenue faster at 36.2% — sustainability is the question.
MDLN generates stronger free cash flow (604M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NEPH scores higher overall (58/100 vs 52/100) and 36.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Nephros Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?